Press Releases

Biophytis Completed Recruitment of 155 Participants to the COVA Phase 2-3 Study with Sarconeos (BIO101) in COVID-19 allowing the 2nd Interim Analysis.

Results of the Combined General Meeting on May 10, 2021

Biophytis – Second Combined General Meeting to Take Place on May 10, 2021 without the physical presence of its shareholders

Biophytis receives €980,000 DeepTech Funding from BPI France for the Development of Macuneos (BIO201) in Dry AMD

Biophytis – Convening of Another Combined General Meeting at a Later Date

Biophytis gives operational perspectives on its Sarconeos (BIO101) ahead of its upcoming AGM on April 26, 2021

Biophytis Identifies False Report Regarding COVA Study

Biophytis gives updates on its Phase 2-3 COVA study on COVID-19

Judgment of the Paris Commercial Court of March 16, 2021 in the case of Biophytis against Negma Group Ltd

Biophytis AGM meeting will take place on April 26, 2021